Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 273

1.

9-ING-41, a small-molecule glycogen synthase kinase-3 inhibitor, is active in neuroblastoma.

Ugolkov AV, Bondarenko GI, Dubrovskyi O, Berbegall AP, Navarro S, Noguera R, O'Halloran TV, Hendrix MJ, Giles FJ, Mazar AP.

Anticancer Drugs. 2018 May 25. doi: 10.1097/CAD.0000000000000652. [Epub ahead of print]

PMID:
29846250
2.

ATP11B mediates platinum resistance in ovarian cancer.

Moreno-Smith M, Halder JB, Meltzer PS, Gonda TA, Mangala LS, Rupaimoole R, Lu C, Nagaraja AS, Gharpure KM, Kang Y, Rodriguez-Aguayo C, Vivas-Mejia PE, Zand B, Schmandt R, Wang H, Langley RR, Jennings NB, Ivan C, Coffin JE, Armaiz GN, Bottsford-Miller J, Kim SB, Halleck MS, Hendrix MJ, Bornman W, Bar-Eli M, Lee JS, Siddik ZH, Lopez-Berestein G, Sood AK.

J Clin Invest. 2018 May 29. pii: 122301. doi: 10.1172/JCI122301. [Epub ahead of print] No abstract available.

3.

Characterization of brain tumor initiating cells isolated from an animal model of CNS primitive neuroectodermal tumors.

Malchenko S, Sredni ST, Boyineni J, Bi Y, Margaryan NV, Guda MR, Kostenko Y, Tomita T, Davuluri RV, Velpula K, Hendrix MJC, Soares MB.

Oncotarget. 2018 Feb 9;9(17):13733-13747. doi: 10.18632/oncotarget.24460. eCollection 2018 Mar 2.

4.

Heterogeneity and Plasticity of Melanoma: Challenges of Current Therapies.

Hendrix MJC, Seftor EA, Margaryan NV, Seftor REB.

In: Ward WH, Farma JM, editors. Cutaneous Melanoma: Etiology and Therapy [Internet]. Brisbane (AU): Codon Publications; 2017 Dec 21. Chapter 4.

5.

Targeting the Stem Cell Properties of Adult Breast Cancer Cells: Using Combinatorial Strategies to Overcome Drug Resistance.

Margaryan NV, Seftor EA, Seftor REB, Hendrix MJC.

Curr Mol Biol Rep. 2017 Sep;3(3):159-164. doi: 10.1007/s40610-017-0067-5. Epub 2017 Jul 10.

PMID:
29152453
6.

An Essential Role of Maspin in Embryogenesis and Tumor Suppression-Response.

Zhang M, Hendrix MJC, Pemberton PA, Sakr WA, Sheng S.

Cancer Res. 2017 Sep 15;77(18):5208-5210. doi: 10.1158/0008-5472.CAN-17-1254. Epub 2017 Sep 6. No abstract available.

PMID:
28877938
7.

Nodal Signaling as a Developmental Therapeutics Target in Oncology.

Kalyan A, Carneiro BA, Chandra S, Kaplan J, Chae YK, Matsangou M, Hendrix MJC, Giles F.

Mol Cancer Ther. 2017 May;16(5):787-792. doi: 10.1158/1535-7163.MCT-16-0215. Review.

8.

Birth place preferences and women's expectations and experiences regarding duration and pain of labor.

van Haaren-Ten Haken TM, Hendrix MJ, Nieuwenhuijze MJ, de Vries RG, Nijhuis JG.

J Psychosom Obstet Gynaecol. 2018 Mar;39(1):19-28. doi: 10.1080/0167482X.2017.1285900. Epub 2017 Feb 6.

PMID:
28165843
9.

Vasculogenic mimicry in small cell lung cancer.

Williamson SC, Metcalf RL, Trapani F, Mohan S, Antonello J, Abbott B, Leong HS, Chester CP, Simms N, Polanski R, Nonaka D, Priest L, Fusi A, Carlsson F, Carlsson A, Hendrix MJ, Seftor RE, Seftor EA, Rothwell DG, Hughes A, Hicks J, Miller C, Kuhn P, Brady G, Simpson KL, Blackhall FH, Dive C.

Nat Commun. 2016 Nov 9;7:13322. doi: 10.1038/ncomms13322.

10.

Targeting melanoma with front-line therapy does not abrogate Nodal-expressing tumor cells.

Hendrix MJ, Kandela I, Mazar AP, Seftor EA, Seftor RE, Margaryan NV, Strizzi L, Murphy GF, Long GV, Scolyer RA.

Lab Invest. 2017 Feb;97(2):176-186. doi: 10.1038/labinvest.2016.107. Epub 2016 Oct 24.

11.

Lefty Glycoproteins in Human Embryonic Stem Cells: Extracellular Delivery Route and Posttranslational Modification in Differentiation.

Khalkhali-Ellis Z, Galat V, Galat Y, Gilgur A, Seftor EA, Hendrix MJ.

Stem Cells Dev. 2016 Sep 19. [Epub ahead of print]

12.

Translational significance of Nodal, Cripto-1 and Notch4 in adult nevi.

Strizzi L, Margaryan NV, Gerami P, Haghighat Z, Harms PW, Madonna G, Botti G, Ascierto PA, Hendrix MJ.

Oncol Lett. 2016 Aug;12(2):1349-1354. Epub 2016 Jun 21.

13.

Transgene Reactivation in Induced Pluripotent Stem Cell Derivatives and Reversion to Pluripotency of Induced Pluripotent Stem Cell-Derived Mesenchymal Stem Cells.

Galat V, Galat Y, Perepitchka M, Jennings LJ, Iannaccone PM, Hendrix MJ.

Stem Cells Dev. 2016 Jul 15;25(14):1060-72. doi: 10.1089/scd.2015.0366. Epub 2016 Jun 27.

14.

Melanocytes Affect Nodal Expression and Signaling in Melanoma Cells: A Lesson from Pediatric Large Congenital Melanocytic Nevi.

Margaryan NV, Gilgur A, Seftor EA, Purnell C, Arva NC, Gosain AK, Hendrix MJ, Strizzi L.

Int J Mol Sci. 2016 Mar 22;17(3):418. doi: 10.3390/ijms17030418.

15.

Nodal expression in triple-negative breast cancer: Cellular effects of its inhibition following doxorubicin treatment.

Bodenstine TM, Chandler GS, Reed DW, Margaryan NV, Gilgur A, Atkinson J, Ahmed N, Hyser M, Seftor EA, Strizzi L, Hendrix MJ.

Cell Cycle. 2016 May 2;15(9):1295-302. doi: 10.1080/15384101.2016.1160981.

16.

Plasticity underlies tumor progression: role of Nodal signaling.

Bodenstine TM, Chandler GS, Seftor RE, Seftor EA, Hendrix MJ.

Cancer Metastasis Rev. 2016 Mar;35(1):21-39. doi: 10.1007/s10555-016-9605-5.

17.

Tumor cell vascular mimicry: Novel targeting opportunity in melanoma.

Hendrix MJ, Seftor EA, Seftor RE, Chao JT, Chien DS, Chu YW.

Pharmacol Ther. 2016 Mar;159:83-92. doi: 10.1016/j.pharmthera.2016.01.006. Epub 2016 Jan 22. Review.

18.

Effects of a novel Nodal-targeting monoclonal antibody in melanoma.

Strizzi L, Sandomenico A, Margaryan NV, Focà A, Sanguigno L, Bodenstine TM, Chandler GS, Reed DW, Gilgur A, Seftor EA, Seftor RE, Khalkhali-Ellis Z, Leonardi A, Ruvo M, Hendrix MJ.

Oncotarget. 2015 Oct 27;6(33):34071-86. doi: 10.18632/oncotarget.6049.

19.

New Anti-Nodal Monoclonal Antibodies Targeting the Nodal Pre-Helix Loop Involved in Cripto-1 Binding.

Focà A, Sanguigno L, Focà G, Strizzi L, Iannitti R, Palumbo R, Hendrix MJ, Leonardi A, Ruvo M, Sandomenico A.

Int J Mol Sci. 2015 Sep 7;16(9):21342-62. doi: 10.3390/ijms160921342.

20.

Cripto-1: an extracellular protein - connecting the sequestered biological dots.

Klauzinska M, Bertolette D, Tippireddy S, Strizzi L, Gray PC, Gonzales M, Duroux M, Ruvo M, Wechselberger C, Castro NP, Rangel MC, Focà A, Sandomenico A, Hendrix MJ, Salomon D, Cuttitta F.

Connect Tissue Res. 2015;56(5):364-80. doi: 10.3109/03008207.2015.1077239. Epub 2015 Sep 1.

PMID:
26327334
21.

Cancer: An extravascular route for tumour cells.

Hendrix MJ.

Nature. 2015 Apr 16;520(7547):300-2. doi: 10.1038/nature14382. Epub 2015 Apr 8. No abstract available.

PMID:
25855292
22.

A mouse model of human primitive neuroectodermal tumors resulting from microenvironmentally-driven malignant transformation of orthotopically transplanted radial glial cells.

Malchenko S, Sredni ST, Hashimoto H, Kasai A, Nagayasu K, Xie J, Margaryan NV, Seiriki K, Lulla RR, Seftor RE, Pachman LM, Meltzer HY, Hendrix MJ, Soares MB.

PLoS One. 2015 Mar 31;10(3):e0121707. doi: 10.1371/journal.pone.0121707. eCollection 2015.

23.

Targeting nodal in conjunction with dacarbazine induces synergistic anticancer effects in metastatic melanoma.

Hardy KM, Strizzi L, Margaryan NV, Gupta K, Murphy GF, Scolyer RA, Hendrix MJ.

Mol Cancer Res. 2015 Apr;13(4):670-80. doi: 10.1158/1541-7786.MCR-14-0077. Epub 2015 Mar 12.

24.

Two Faces of Cathepsin D: Physiological Guardian Angel and Pathological Demon.

Khalkhali-Ellis Z, Hendrix MJ.

Biol Med (Aligarh). 2014 Jul;6(2). pii: 1000206.

25.

Genetic analysis of the 'uveal melanoma' C918 cell line reveals atypical BRAF and common KRAS mutations and single tandem repeat profile identical to the cutaneous melanoma C8161 cell line.

Yu X, Ambrosini G, Roszik J, Eterovic AK, Stempke-Hale K, Seftor EA, Chattopadhyay C, Grimm E, Carvajal RD, Hendrix MJ, Hodi FS, Schwartz GK, Woodman SE.

Pigment Cell Melanoma Res. 2015 May;28(3):357-9. doi: 10.1111/pcmr.12345. Epub 2015 Mar 23. No abstract available.

PMID:
25515650
26.

Internalization by multiple endocytic pathways and lysosomal processing impact maspin-based therapeutics.

Bodenstine TM, Seftor RE, Seftor EA, Khalkhali-Ellis Z, Samii NA, Monarrez JC, Chandler GS, Pemberton PA, Hendrix MJ.

Mol Cancer Res. 2014 Oct;12(10):1480-91. doi: 10.1158/1541-7786.MCR-14-0067. Epub 2014 Sep 25.

27.

Divergence(s) in nodal signaling between aggressive melanoma and embryonic stem cells.

Khalkhali-Ellis Z, Kirschmann DA, Seftor EA, Gilgur A, Bodenstine TM, Hinck AP, Hendrix MJ.

Int J Cancer. 2015 Mar 1;136(5):E242-51. doi: 10.1002/ijc.29198. Epub 2014 Sep 29.

28.

Oncofetal signaling as a target for cancer therapy.

Ahrlund-Richter L, Hendrix MJ.

Semin Cancer Biol. 2014 Dec;29:1-2. doi: 10.1016/j.semcancer.2014.08.001. Epub 2014 Aug 8. No abstract available.

PMID:
25111377
29.

Nodal signaling promotes a tumorigenic phenotype in human breast cancer.

Kirsammer G, Strizzi L, Margaryan NV, Gilgur A, Hyser M, Atkinson J, Kirschmann DA, Seftor EA, Hendrix MJ.

Semin Cancer Biol. 2014 Dec;29:40-50. doi: 10.1016/j.semcancer.2014.07.007. Epub 2014 Jul 26. Review.

30.

Characterization of cancer stem-like cells derived from mouse induced pluripotent stem cells transformed by tumor-derived extracellular vesicles.

Yan T, Mizutani A, Chen L, Takaki M, Hiramoto Y, Matsuda S, Shigehiro T, Kasai T, Kudoh T, Murakami H, Masuda J, Hendrix MJ, Strizzi L, Salomon DS, Fu L, Seno M.

J Cancer. 2014 Jul 5;5(7):572-84. doi: 10.7150/jca.8865. eCollection 2014.

31.

Cleavage of Histone 3 by Cathepsin D in the involuting mammary gland.

Khalkhali-Ellis Z, Goossens W, Margaryan NV, Hendrix MJ.

PLoS One. 2014 Jul 23;9(7):e103230. doi: 10.1371/journal.pone.0103230. eCollection 2014.

32.

Melanoma tumor cell heterogeneity: a molecular approach to study subpopulations expressing the embryonic morphogen nodal.

Seftor EA, Seftor REB, Weldon D, Kirsammer GT, Margaryan NV, Gilgur A, Hendrix MJC.

Semin Oncol. 2014 Apr;41(2):259-266. doi: 10.1053/j.seminoncol.2014.02.001. Epub 2014 Feb 7. Review.

33.

Age-Dependent Association between Protein Expression of the Embryonic Stem Cell Marker Cripto-1 and Survival of Glioblastoma Patients.

Tysnes BB, Satran HA, Mork SJ, Margaryan NV, Eide GE, Petersen K, Strizzi L, Hendrix MJ.

Transl Oncol. 2013 Dec 1;6(6):732-41. eCollection 2013 Dec 1.

34.

Onset of rosette formation during spontaneous neural differentiation of hESC and hiPSC colonies.

Malchenko S, Xie J, de Fatima Bonaldo M, Vanin EF, Bhattacharyya BJ, Belmadani A, Xi G, Galat V, Goossens W, Seftor RE, Tomita T, Crispino J, Miller RJ, Bohn MC, Hendrix MJ, Soares MB.

Gene. 2014 Jan 25;534(2):400-7. doi: 10.1016/j.gene.2013.07.101. Epub 2013 Aug 15.

35.

Neuroblastoma cells injected into experimental mature teratoma reveal a tropism for embryonic loose mesenchyme.

Jamil S, Cedervall J, Hultman I, Ali R, Margaryan NV, Rasmuson A, Johnsen JI, Sveinbjörnsson B, Dalianis T, Kanter L, Orrego A, Strizzi L, Hendrix MJ, Sandstedt B, Kogner P, Ahrlund-Richter L.

Int J Oncol. 2013 Sep;43(3):831-8. doi: 10.3892/ijo.2013.2014. Epub 2013 Jul 12.

PMID:
23857308
36.

ATP11B mediates platinum resistance in ovarian cancer.

Moreno-Smith M, Halder JB, Meltzer PS, Gonda TA, Mangala LS, Rupaimoole R, Lu C, Nagaraja AS, Gharpure KM, Kang Y, Rodriguez-Aguayo C, Vivas-Mejia PE, Zand B, Schmandt R, Wang H, Langley RR, Jennings NB, Ivan C, Coffin JE, Armaiz GN, Bottsford-Miller J, Kim SB, Halleck MS, Hendrix MJ, Bornman W, Bar-Eli M, Lee JS, Siddik ZH, Lopez-Berestein G, Sood AK.

J Clin Invest. 2013 May;123(5):2119-30. doi: 10.1172/JCI65425. Epub 2013 Apr 15.

37.

The significance of a Cripto-1 positive subpopulation of human melanoma cells exhibiting stem cell-like characteristics.

Strizzi L, Margaryan NV, Gilgur A, Hardy KM, Normanno N, Salomon DS, Hendrix MJ.

Cell Cycle. 2013 May 1;12(9):1450-6. doi: 10.4161/cc.24601. Epub 2013 Apr 10.

38.

Tumor cell vasculogenic mimicry: from controversy to therapeutic promise.

Seftor RE, Hess AR, Seftor EA, Kirschmann DA, Hardy KM, Margaryan NV, Hendrix MJ.

Am J Pathol. 2012 Oct;181(4):1115-25. doi: 10.1016/j.ajpath.2012.07.013. Epub 2012 Aug 31. Review.

39.

Maspin: molecular mechanisms and therapeutic implications.

Bodenstine TM, Seftor RE, Khalkhali-Ellis Z, Seftor EA, Pemberton PA, Hendrix MJ.

Cancer Metastasis Rev. 2012 Dec;31(3-4):529-51. doi: 10.1007/s10555-012-9361-0. Review.

PMID:
22752408
40.

Potential for the embryonic morphogen Nodal as a prognostic and predictive biomarker in breast cancer.

Strizzi L, Hardy KM, Margaryan NV, Hillman DW, Seftor EA, Chen B, Geiger XJ, Thompson EA, Lingle WL, Andorfer CA, Perez EA, Hendrix MJ.

Breast Cancer Res. 2012 May 11;14(3):R75.

41.

A model of cancer stem cells derived from mouse induced pluripotent stem cells.

Chen L, Kasai T, Li Y, Sugii Y, Jin G, Okada M, Vaidyanath A, Mizutani A, Satoh A, Kudoh T, Hendrix MJ, Salomon DS, Fu L, Seno M.

PLoS One. 2012;7(4):e33544. doi: 10.1371/journal.pone.0033544. Epub 2012 Apr 12.

42.

Nodal expression and detection in cancer: experience and challenges.

Strizzi L, Hardy KM, Kirschmann DA, Ahrlund-Richter L, Hendrix MJ.

Cancer Res. 2012 Apr 15;72(8):1915-20. doi: 10.1158/0008-5472.CAN-11-3419. Review.

43.

Molecular pathways: vasculogenic mimicry in tumor cells: diagnostic and therapeutic implications.

Kirschmann DA, Seftor EA, Hardy KM, Seftor RE, Hendrix MJ.

Clin Cancer Res. 2012 May 15;18(10):2726-32. doi: 10.1158/1078-0432.CCR-11-3237. Epub 2012 Apr 2.

44.

Putative multifunctional signature of lung metastases in dedifferentiated chondrosarcoma.

Malchenko S, Seftor EA, Nikolsky Y, Hasegawa SL, Kuo S, Stevens JW, Poyarkov S, Nikolskaya T, Kucaba T, Wang M, Abdulkawy H, Casavant T, Morcuende J, Buckwalter J, Hohl R, Deyoung B, Kernstine K, Bonaldo Mde F, Hendrix MJ, Soares MB, Soares VM.

Sarcoma. 2012;2012:820254. doi: 10.1155/2012/820254. Epub 2012 Feb 16.

45.

Expression and functional role of CRIPTO-1 in cutaneous melanoma.

De Luca A, Lamura L, Strizzi L, Roma C, D'Antonio A, Margaryan N, Pirozzi G, Hsu MY, Botti G, Mari E, Hendrix MJ, Salomon DS, Normanno N.

Br J Cancer. 2011 Sep 27;105(7):1030-8. doi: 10.1038/bjc.2011.324. Epub 2011 Aug 23.

46.

A model of early human embryonic stem cell differentiation reveals inter- and intracellular changes on transition to squamous epithelium.

Galat V, Malchenko S, Galat Y, Ishkin A, Nikolsky Y, Kosak ST, Soares BM, Iannaccone P, Crispino JD, Hendrix MJ.

Stem Cells Dev. 2012 May 20;21(8):1250-63. doi: 10.1089/scd.2010.0578. Epub 2011 Oct 19.

47.

Reactivation of embryonic nodal signaling is associated with tumor progression and promotes the growth of prostate cancer cells.

Lawrence MG, Margaryan NV, Loessner D, Collins A, Kerr KM, Turner M, Seftor EA, Stephens CR, Lai J; APC BioResource, Postovit LM, Clements JA, Hendrix MJ.

Prostate. 2011 Aug 1;71(11):1198-209. doi: 10.1002/pros.21335. Epub 2011 Jan 12.

48.

Embryonic signaling in melanoma: potential for diagnosis and therapy.

Strizzi L, Hardy KM, Kirsammer GT, Gerami P, Hendrix MJ.

Lab Invest. 2011 Jun;91(6):819-24. doi: 10.1038/labinvest.2011.63. Epub 2011 Apr 4.

49.

Tumor reversion holds promise.

Telerman A, Amson R, Hendrix MJ.

Oncotarget. 2010 Aug;1(4):233-4. No abstract available.

50.

Regulation of the embryonic morphogen Nodal by Notch4 facilitates manifestation of the aggressive melanoma phenotype.

Hardy KM, Kirschmann DA, Seftor EA, Margaryan NV, Postovit LM, Strizzi L, Hendrix MJ.

Cancer Res. 2010 Dec 15;70(24):10340-50. doi: 10.1158/0008-5472.CAN-10-0705.

Supplemental Content

Loading ...
Support Center